Literature DB >> 23532365

Role of the new oral anticoagulants in treatment of venous throboembolism.

Tracy Minichiello1, David Garcia.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23532365     DOI： 10.1007/s11239-013-0916-x

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  10 in total

1.  Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Gordon H Guyatt; Elie A Akl; Mark Crowther; David D Gutterman; Holger J Schuünemann
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

Authors:  Harry R Büller; Martin H Prins; Anthonie W A Lensin; Hervé Decousus; Barry F Jacobson; Erich Minar; Jaromir Chlumsky; Peter Verhamme; Phil Wells; Giancarlo Agnelli; Alexander Cohen; Scott D Berkowitz; Henri Bounameaux; Bruce L Davidson; Frank Misselwitz; Alex S Gallus; Gary E Raskob; Sebastian Schellong; Annelise Segers
Journal:  N Engl J Med       Date:  2012-03-26       Impact factor: 91.245

3.  Oral rivaroxaban for symptomatic venous thromboembolism.

Authors:  Rupert Bauersachs; Scott D Berkowitz; Benjamin Brenner; Harry R Buller; Hervé Decousus; Alex S Gallus; Anthonie W Lensing; Frank Misselwitz; Martin H Prins; Gary E Raskob; Annelise Segers; Peter Verhamme; Phil Wells; Giancarlo Agnelli; Henri Bounameaux; Alexander Cohen; Bruce L Davidson; Franco Piovella; Sebastian Schellong
Journal:  N Engl J Med       Date:  2010-12-03       Impact factor: 91.245

4.  Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study).

Authors:  Erica Romualdi; Marco P Donadini; Walter Ageno
Journal:  Expert Rev Cardiovasc Ther       Date:  2011-07

Review 5.  Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials.

Authors:  Ken Uchino; Adrian V Hernandez
Journal:  Arch Intern Med       Date:  2012-01-09

Review 6.  Long-term management of patients after venous thromboembolism.

Authors:  Clive Kearon
Journal:  Circulation       Date:  2004-08-31       Impact factor: 29.690

7.  Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.

Authors:  Sam Schulman; Clive Kearon; Ajay K Kakkar; Sebastian Schellong; Henry Eriksson; David Baanstra; Anne Mathilde Kvamme; Jeffrey Friedman; Patrick Mismetti; Samuel Z Goldhaber
Journal:  N Engl J Med       Date:  2013-02-21       Impact factor: 91.245

8.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

Authors:  Sam Schulman; Clive Kearon; Ajay K Kakkar; Patrick Mismetti; Sebastian Schellong; Henry Eriksson; David Baanstra; Janet Schnee; Samuel Z Goldhaber
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

9.  Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.

Authors:  Agnes Y Y Lee; Mark N Levine; Ross I Baker; Chris Bowden; Ajay K Kakkar; Martin Prins; Frederick R Rickles; Jim A Julian; Susan Haley; Michael J Kovacs; Michael Gent
Journal:  N Engl J Med       Date:  2003-07-10       Impact factor: 91.245

10.  Apixaban for extended treatment of venous thromboembolism.

Authors:  Giancarlo Agnelli; Harry R Buller; Alexander Cohen; Madelyn Curto; Alexander S Gallus; Margot Johnson; Anthony Porcari; Gary E Raskob; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2012-12-08       Impact factor: 91.245
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.